Oppenheimer Increases HCA Healthcare (NYSE:HCA) Price Target to $400.00

HCA Healthcare (NYSE:HCA) had its price target raised by stock analysts at Oppenheimer from $390.00 to $400.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target indicates a potential upside of 10.22% from the company’s previous close.

A number of other research firms also recently issued reports on HCA. Wells Fargo & Company boosted their price objective on shares of HCA Healthcare from $365.00 to $395.00 and gave the company an “equal weight” rating in a report on Tuesday, October 22nd. Wolfe Research raised HCA Healthcare to a “strong-buy” rating in a research report on Thursday, August 29th. UBS Group upped their target price on HCA Healthcare from $405.00 to $438.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $392.00 price target on shares of HCA Healthcare in a research note on Tuesday, October 1st. Finally, Royal Bank of Canada lifted their price objective on shares of HCA Healthcare from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Friday, August 23rd. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $374.67.

HCA Healthcare Stock Down 0.2 %

HCA stock opened at $362.90 on Monday. The company has a debt-to-equity ratio of 27.11, a current ratio of 1.06 and a quick ratio of 0.94. The business’s fifty day moving average price is $395.06 and its two-hundred day moving average price is $352.71. HCA Healthcare has a fifty-two week low of $222.23 and a fifty-two week high of $417.14. The stock has a market capitalization of $95.05 billion, a price-to-earnings ratio of 18.09, a PEG ratio of 1.52 and a beta of 1.67.

Insider Transactions at HCA Healthcare

In other HCA Healthcare news, SVP Kathleen M. Whalen sold 2,987 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $363.51, for a total value of $1,085,804.37. Following the transaction, the senior vice president now owns 9,454 shares in the company, valued at approximately $3,436,623.54. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Michael S. Cuffe sold 8,358 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total value of $3,221,340.36. Following the transaction, the executive vice president now owns 29,678 shares in the company, valued at $11,438,494.76. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Kathleen M. Whalen sold 2,987 shares of HCA Healthcare stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $363.51, for a total transaction of $1,085,804.37. Following the completion of the sale, the senior vice president now directly owns 9,454 shares in the company, valued at $3,436,623.54. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On HCA Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in HCA. NorthRock Partners LLC grew its position in HCA Healthcare by 17.4% in the first quarter. NorthRock Partners LLC now owns 1,310 shares of the company’s stock worth $437,000 after acquiring an additional 194 shares in the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH increased its position in shares of HCA Healthcare by 2,471.9% during the 1st quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 7,690 shares of the company’s stock valued at $2,565,000 after purchasing an additional 7,391 shares during the last quarter. Hedeker Wealth LLC boosted its stake in HCA Healthcare by 0.8% in the first quarter. Hedeker Wealth LLC now owns 11,117 shares of the company’s stock worth $3,708,000 after buying an additional 89 shares in the last quarter. Carret Asset Management LLC raised its stake in shares of HCA Healthcare by 1.9% during the first quarter. Carret Asset Management LLC now owns 10,095 shares of the company’s stock worth $3,367,000 after acquiring an additional 190 shares in the last quarter. Finally, Denali Advisors LLC grew its holdings in shares of HCA Healthcare by 14.3% during the 1st quarter. Denali Advisors LLC now owns 2,400 shares of the company’s stock valued at $800,000 after purchasing an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 62.73% of the company’s stock.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.